HHLA2 Antibody - #DF14396

(1)   (3)  
Product: HHLA2 Antibody
Catalog: DF14396
Description: Rabbit polyclonal antibody to HHLA2
Application: IHC IF/ICC
Cited expt.: IF/ICC
Reactivity: Human
Mol.Wt.: 47kD(Calculated).
Uniprot: Q9UM44

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human
Clonality:
Polyclonal
Specificity:
HHLA2 Antibody detects endogenous levels of total HHLA2.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

B7H7; HERV H LTR associating 2; HERV-H LTR-associating protein 2; HHLA 2; HHLA2; HHLA2_HUMAN; Human endogenous retrovirus H long terminal repeat associating protein 2; Human endogenous retrovirus-H long terminal repeat-associating protein 2;

Immunogens

Immunogen:

A synthesized peptide derived from Human HHLA2.

Uniprot:

Q9UM44(HHLA2_HUMAN) >>Visit HPA database.

Gene(ID):
HHLA2(11148)
Expression:
Q9UM44 HHLA2_HUMAN:

Expressed at high levels in colon, kidney, testis, lung and pancreas, and at lower levels in small intestine, liver and skeletal muscle. In immune cells, highly expressed in B-cells, dendritic cells and macrophages. Not detected in T-cells.

Sequence:
MKAQTALSFFLILITSLSGSQGIFPLAFFIYVPMNEQIVIGRLDEDIILPSSFERGSEVVIHWKYQDSYKVHSYYKGSDHLESQDPRYANRTSLFYNEIQNGNASLFFRRVSLLDEGIYTCYVGTAIQVITNKVVLKVGVFLTPVMKYEKRNTNSFLICSVLSVYPRPIITWKMDNTPISENNMEETGSLDSFSINSPLNITGSNSSYECTIENSLLKQTWTGRWTMKDGLHKMQSEHVSLSCQPVNDYFSPNQDFKVTWSRMKSGTFSVLAYYLSSSQNTIINESRFSWNKELINQSDFSMNLMDLNLSDSGEYLCNISSDEYTLLTIHTVHVEPSQETASHNKGLWILVPSAILAAFLLIWSVKCCRAQLEARRSRHPADGAQQERCCVPPGERCPSAPDNGEENVPLSGKV

Research Backgrounds

Function:

Through interaction with TMIGD2, costimulates T-cells in the context of TCR-mediated activation. Enhances T-cell proliferation and cytokine production via an AKT-dependent signaling cascade.

Subcellular Location:

Membrane>Single-pass type I membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed at high levels in colon, kidney, testis, lung and pancreas, and at lower levels in small intestine, liver and skeletal muscle. In immune cells, highly expressed in B-cells, dendritic cells and macrophages. Not detected in T-cells.

References

1). Histone lactylation dynamics: Unlocking the triad of metabolism, epigenetics, and immune regulation in metastatic cascade of pancreatic cancer. Cancer letters, 2024 (PubMed: 39019144) [IF=9.1]

Application: IF/ICC    Species: Mouse    Sample:

Fig. 9. Increased HLS in metastasized cells presented with enhanced immune evasion (A–B) Representative multi-color staining of PRM and LMT. Panel1: CK19 (blue), HHLA2 (brown), Pan Kla (grey), NCAM1 (yellow), Galectin-9 (green), and B7H3 (red) (A). Panel2: CK19 (grey), PDL1 (brown), B7H4 (pink), Nectin-2 (yellow), CD3 (green), and CD8 (red) (B) (C–E) Correlation of tumor nuclear score of Pan Kla and mesenchymal proportion of NK, CD8+ T cells and CD8+/CD3+CD8− T cells ratio in PRM and LMT. (F) Circle diagram showing that correlation of IHC score of Pan Kla and other immune checkpoints. (G) Violin diagram showing that difference of mesenchymal and parenchymal score and discrepancy of PRM and LMT. (H) Scatter plot displaying nuclear score of Pan Kla and cytoplastic score of Netin-2 in PRM and LMT. (I) Heatmap showing cytoplastic score of Pan Kla and cytoplastic score of checkpoints and immune infiltration in PRM and LMT. (J) K-M survival analysis of TMA validation cohort. (K) Correlation of immune parameters and Pan Kla score in TMA validation cohort. (L) Distance distribution between Nectin-2+ CK19+ cells and CD8+ T cells in high and low Pan Kla group. (M) Heatmap show the difference in the number and intensity of interactions per cell cluster at PRM and LMT. (N) Comparison of immune-related function in PRM and LMT. MCS, mesenchymal cytoplastic score; MNS, mesenchymal nuclear score; PRM, primary lesions; LMT, liver metastasis; HLS, histone lactylation score; TMA, tissue microarray.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.